Alefacept treatment in psoriatic arthritis: Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis

Arthritis and Rheumatism

Volumn 46, Issue 10, 2002, Pages 2776-2784

  Kraan, Maarten C ^a   van Kuijk, Arno W R ^b   Dinant, Huibert J ^a   Goedkoop, Amber Y ^a   Smeets, Tom J M ^a   de Rie, Menno A ^a   Dijkmans, Ben A C ^b   Vaishnaw, Akshay K ^c   Bos, Jan D ^a   Tak, Paul P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT;

ADULT; AGED; ARTHROSCOPY; ARTICLE; CELL INFILTRATION; CHRONIC ARTHRITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN TISSUE; INFECTION; LYMPHOCYTE COUNT; MACROPHAGE; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SYMPTOMATOLOGY; SYNOVITIS; SYNOVIUM; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ANTIGENS, CD4; ANTIGENS, CD45; ARTHRITIS, PSORIATIC; ARTHROSCOPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; SYNOVIAL MEMBRANE; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0036822279     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10543     Document Type: Article

References (52)

1. Wright V, Psoriatic arthritis. Ann Rheum Dis 1961;20:123-32.
2. Espinoza LR, Cuellar ML, Silveira LH. Psoriatic arthritis. Curr Opin Rheumatol 1992;4:470-8.
3. Bruce IN, Silman AJ. The aetiology of psoriatic arthritis. Rheumatology (Oxford) 2001;40:363-6.
4. Clegg DO, Reda DJ, Meijas E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996;39:2013-20.
5. Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davies D, Bacon PA. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study [letter]. Br J Rheumatol 1990;29:46-9.
6. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
7. Espinoza LR, Zakraoui L, Espinoza CG, Gutierrez F, Jara LJ, Silveira LH, et al. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 1992;19:872-7.
8. Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995;13:589-93.
9. Steinsson K, Jonsdottir I, Valdimarsson H. Cyclosporin A in psoriatic arthritis: an open study. Ann Rheum Dis 1990;49:603-6.
10. Breedveld FC. Future trends in the treatment of rheumatoid arthritis: cytokine targets. Rheumatology (Oxford) 1999;38 Suppl 2:11-3.
11. Emery P. Therapeutic approaches for early rheumatoid arthritis. How early? How aggressive? Br J Rheumatol 1995;34:87-90.
12. Mease PJ, Goffe BS, Metz J, van der Stoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000;356:385-90.
13. Tak PP. Examination of the synovium and synovial fluid. In: Firestein GS, Panayi GS, Wollheim FA, editors. Rheumatoid arthritis: frontiers in pathogenesis and treatment. New York: Oxford University Press; 2000. p. 55-68.
14. Tak PP. Lessons learnt from the synovial tissue response to anti-rheumatic treatment. Rheumatology (Oxford) 2000;39:817-20.
15. Patel S, Veale D, FitzGerald O, McHugh NJ. Psoriatic arthritis: emerging concepts. Rheumatology (Oxford) 2001;40:243-6.
16. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994;102:145-9.
17. Jackson M, Howie SE, Weller R, Sabin E, Hunter JA, McKenzie RC. Psoriatic keratinocytes show reduced IRF-1 and STAT-1α activation in response to γ-IFN. FASEB J 1999;13:495-502.
18. Costello PJ, Winchester RJ, Curran SA, Peterson KS, Kane DJ, Bresnihan B, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions that appear antigen driven. J Immunol 2001;166:2878-86.
19. Partsch G, Wagner E, Leeb BF, Broll H, Dunky A, Smolen JS. T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis 1998;57:691-3.
20. Tassiulas I, Duncan SR, Centola M, Theofilopoulos AN, Boumpas DT. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 1999;60:479-91.
21. Chisholm PL, Williams CA, Jones WE, Majeau GR, Oleson FB, Burrus-Fischer B, et al. The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates. Ther Immunol 1994;1:205-16.
22. Meier W, Gill A, Rogge M, Dabora R, Majeau GR, Oleson FB, et al. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther Immunol 1995;2:159-71.
23. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses: structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994;152:2753-67.
24. Kaplon RJ, Hochman PS, Michler RE, Kwiatkowski PA, Edwards NM, Berger CL, et al. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. Transplantation 1996;61:356-63.
25. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993;178:211-22.
26. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55.
27. Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995;38:38-43.
28. Van Riel PL, van Gestel AM. Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 2000;59 Suppl 1:i28-31.
29. Bresnihan B, Tak PP, Emery P, Klareskog L, Breedveld F. Synovial biopsy in arthritis research: five years of concerted European collaboration. Ann Rheum Dis 2000;59:506-11.
30. Kraan MC, Reece RJ, Smeets TJ, Veale DJ, Emery P, Tak PP. Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: implications for pathogenesis and evaluation of treatment. Arthritis Rheum 2002;46:2034-8.
31. Ostendorf B, Peters R, Dann P, Becker A, Scherer A, Wedekind F, et al. Magnetic resonance imaging and miniarthroscopy of metacarpophalangeal joints: sensitive detection of morphologic changes in rheumatoid arthritis. Arthritis Rheum 2001;44:2492-502.
32. Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis: findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000;43:1820-30.
33. Dolhain RJ, Ter Haar NT, de Kuiper R, Nieuwenhuis IG, Zwinderman AH, Breedveld FC, et al. Distribution of T cells and signs of T-cell activation in the rheumatoid joint: implications for semiquantitative comparative histology. Br J Rheumatol 1998;37:324-30.
34. Youssef PP, Kraan M, Breedveld F, Bresnihan B, Cassidy N, Cunnane G, et al. Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy. Arthritis Rheum 1998;41:663-9.
35. Kraan MC, Versendaal H, Jonker M, Bresnihan B, Post WJ, 't Hart BA, et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum 1998;41:1481-8.
36. Kraan MC, Haringman JJ, Ahern MJ, Breedveld FC, Smith MD, Tak PP. Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxford) 2000;39:43-9.
37. Kraan MC, Smith MD, Weedon H, Ahern MJ, Breedveld FC, Tak PP. Measurement of cytokine and adhesion molecule expression in synovial tissue by digital image analysis. Ann Rheum Dis 2001;60:296-8.
38. Tak PP, Kummer JA, Hack CE, Daha MR, Smeets TJ, Erkelens GW, et al. Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum 1994;37:1735-43.
39. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
40. Fredricksson T, Petterson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
41. Epstein WV. Expectation bias in rheumatoid arthritis clinical trials: the anti-CD4 monoclonal antibody experience. Arthritis Rheum 1996;39:1773-80.
42. Ruderman EM, Weinblatt ME, Thurmond LM, Pinkus GS, Gravallese EM. Synovial tissue response to treatment with Campath-1H. Arthritis Rheum 1995;38:254-8.
43. Smeets TJ, Kraan MC, Versendaal J, Breedveld FC, Tak PP. Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo. J Rheumatol 1999;26:2089-93.
44. Cunnane G, Madigan A, Murphy E, FitzGerald O, Bresnihan B. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford) 2001;40:62-9.
45. Tak PP, van der Lubbe PA, Cauli A, Daha MR, Smeets TJ, Kluin PM, et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995;38:1457-65.
46. Youssef PP, Smeets TJ, Bresnihan B, Cunnane G, FitzGerald O, Breedveld F, et al. Microscopic measurement of cellular inflammation in the rheumatoid arthritis synovial membrane: a comparison of semiquantitative and quantitative analysis. Br J Rheumatol 1998;37:1003-7.
47. Bresnihan B, Tak PP. Synovial tissue analysis in rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 1999;13:645-59.
48. Van der Lubbe PA, Dijkmans BA, Markusse HM, Nassander U, Breedveld FC. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995;38:1097-106.
49. Van der Lubbe PA, Breedveld FC, Tak PP, Schantz A, Woody J, Miltenburg AM. Treatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4+/CD45RA+ cells in patients with rheumatoid arthritis. J Autoimmun 1997;10:87-97.
50. Rep MH, van Oosten BW, Roos MT, Ader HJ, Polman CH, van Lier RA. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-γ secreting TH1 cells in humans. J Clin Invest 1997;99:2225-31.
51. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to disease activity. Arthritis Rheum 1997;40:217-25.
52. Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor a monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1077-81.